PRVA · Privia Health Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $138.15M | $126.16M | $109.59M | $129.59M | $44.02M |
| Total Operating Expenses | $2.09B | $1.72B | $1.64B | $1.38B | $791.70M |
| D&A | $9.91M | $7.27M | $6.53M | $4.57M | $1.84M |
| Operating Income | $34.23M | $16.98M | $20.65M | ($19.12M) | $25.38M |
| Interest Expense | - | - | - | $500.0K | $1.90M |
| Income Tax | $14.21M | $10.83M | $7.99M | ($6.52M) | ($7.44M) |
| Net Income | $22.92M | $14.38M | $23.08M | ($8.59M) | $31.24M |
| EPS - Basic | $0.19 | $0.12 | $0.20 | ($0.08) | $0.33 |
| EPS - Diluted | $0.18 | $0.11 | $0.19 | ($0.08) | $0.33 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $479.69M | $491.15M | $389.51M | $347.99M | $320.58M |
| Accounts Receivable | $400.90M | $316.18M | $290.77M | $189.60M | $117.40M |
| Inventory | - | - | - | - | - |
| Accounts Payable | $7.97M | $9.76M | $7.88M | $6.73M | $2.97M |
| Current Assets | $911.00M | $834.82M | $700.80M | $551.96M | $446.68M |
| Total Assets | $1.37B | $1.14B | $999.90M | $792.81M | $686.37M |
| Current Liabilities | $568.52M | $449.15M | $386.95M | $264.27M | $190.46M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $578.43M | $452.34M | $392.51M | $273.76M | $236.19M |
| Stockholders' Equity | $737.22M | $635.18M | $561.44M | $499.09M | $426.87M |
| Retained Earnings | ($156.31M) | ($179.23M) | ($193.61M) | ($216.69M) | ($208.11M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $163.40M | $109.28M | $80.78M | $47.20M | $38.89M |
| Investing Cash Flow | ($181.57M) | ($11.98M) | ($42.97M) | ($104.0K) | ($380.0K) |
| Financing Cash Flow | $6.70M | $4.33M | $3.71M | ($19.68M) | ($767.0K) |
| CapEx | - | - | $113.0K | $104.0K | $380.0K |
| Free Cash Flow | - | - | $80.67M | $47.09M | $38.51M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | 3.50 | -5.49 | 1.23 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | 38.3% | 42.9% | 25.7% | - | -31.3% |
| Return on assets | 1.7% | 1.3% | 2.3% | -1.1% | 4.6% |
| Return on equity | 3.1% | 2.3% | 4.1% | -1.7% | 7.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 1.60 | 1.86 | 1.81 | 2.09 | 2.35 |
| Quick ratio | 1.60 | 1.86 | 1.81 | 2.09 | 2.35 |
| Cash ratio | 0.84 | 1.09 | 1.01 | 1.32 | 1.68 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | -38.2x | 13.4x |
| Equity multiplier | 1.86 | 1.79 | 1.78 | 1.59 | 1.61 |
| Liabilities / Assets | 0.42 | 0.40 | 0.39 | 0.35 | 0.34 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | 131.7x | 177.7x | 121.2x | - | 78.4x |
| P / B | 4.1x | 3.9x | 5.1x | 5.0x | 5.8x |
| P / S | - | - | - | - | - |
| EV / EBITDA | 58.4x | 81.0x | 91.3x | - | 79.4x |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 101.6% | -17.8% | - | - | - |
| Net income growth (YoY) | 59.3% | -37.7% | - | - | - |
| EPS growth (YoY) | 63.6% | -42.1% | - | - | - |
| EPS CAGR (3y) | - | -30.7% | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | 71.3% | 22.3% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 16.1% | 13.1% | 12.5% | 16.9% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Health Services
Comparing Privia Health Group against the 5 most active filers in the same SIC group.